FOR IMMEDIATE RELEASE
October 13, 2023
Ponte Vedra, FL – HEMOTAG, a non-invasive and portable structural heart health monitoring device, took the first place on the Bio Pitch during the 2023 BioFlorida Conference on October 13, 2023. Out of an impressive 66 companies who applied for the competition, 16 companies were selected to participate in the pitch event. The competition unfolded in a multi-tiered format, with the 16 selected companies presenting their groundbreaking ideas to a room filled with investors. After rigorous deliberations, HEMOTAG advanced to the final stage where the top 4 companies showcased their innovations to another set of investors and the Bio Florida attendees.
In a resounding validation of HEMOTAG, a revolutionary device to measure structural heart health in 30 seconds, the company’s presentation captured the attention of the investor panel. Selected as the ultimate winner of the Bio Pitch Competition 2023.
“We are thrilled and honored to have been selected as the winner of the Bio Pitch Competition 2023” said Kaustubh Kale, Founder and CEO. “HEMOTAG provides absolute, accurate and actionable vitals for heart failure, which previously were available only via surgical implants, or blood draws; HEMOTAG changes the game, and we are glad everyone agrees of the magnitude of this change”.
HEMOTAG looks forward to utilizing this prestigious accolade as a springboard for future growth, innovation, and partnership opportunities within the Heart Failure MedTech industry.
HEMOTAG Vitals is available for adult use in the US.
About HEMOTAG Vitals
HEMOTAG Vitals is the future of non-invasive cardiac hemodynamic monitoring. Providing heart failure vitals using proprietary non-invasive and the industry’s first and only quad-sensing vibration technology, which previously were available only through surgical procedures or blood draws. HEMOTAG sees beyond the gold-standard invasive procedures and implantable devices, with our mission to revolutionize the way we can respond to structural heart disease and heart failure in the coming decade.
About Aventusoft
Founded on engineering first principles, combining biologically inspired hardware and software; with AI and Cloud Computing. Their HEMOTAG Vitals product provides rapid vitals to identify and monitor structural heart health; in cardiovascular & metabolic diseases, coordinated care and clinical trials. Aventusoft is located in the Research Park at Florida Atlantic University.
About BioFlorida
BioFlorida is the voice of Florida’s life sciences industry, representing 8,600 establishments and research organizations in BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians.
BioFlorida’s member driven initiatives provide a strong business climate for the advancement of innovative products and technology that improve lives and promote economic benefits to the state.
For media inquiries contact:
Kaustubh Kale
Founder and CEO
HEMOTAG
kkale@hemotag.com
561.234.4040
###
